{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:25:58Z","timestamp":1794288358169,"version":"4.9.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002203","name":"The Brain Tumor Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01098","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:33:07Z","timestamp":1791797587000},"page":"e01098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Meningioma in the modern era: Updates in stratification and therapeutic approaches"],"prefix":"10.1016","volume":"23","author":[{"given":"Leeor S.","family":"Yefet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12 Suppl 2","key":"10.1016\/j.neurot.2026.e01098_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01098_bib2","article-title":"Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for Clinicians, researchers, and patients","author":"Wang","year":"2024","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01098_bib3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7874","key":"10.1016\/j.neurot.2026.e01098_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley","year":"2022","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01098_bib10","article-title":"Validation and next-generation update of a DNA methylation\u2013based recurrence predictor for meningioma: a multicenter prospective study","volume":"6","author":"Landry","year":"2024","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01098_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jnen\/nlv006","article-title":"Meningiomas with rhabdoid features lacking other histologic features of malignancy: A study of 44 cases and review of the literature","volume":"75","author":"Vaubel","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"6123","key":"10.1016\/j.neurot.2026.e01098_bib15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of Non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00401-024-02777-z","article-title":"Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma","volume":"148","author":"Maas","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01098_bib18","series-title":"Spatially resolved single cell analyses of human meningioma identify novel cell states influencing tumor microenvironment and progression","author":"Landry","year":"2026"},{"key":"10.1016\/j.neurot.2026.e01098_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.0329","article-title":"Chromosome 1p loss and 1q gain for grading of meningioma","author":"Landry","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01098_bib20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","article-title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","volume":"26","author":"Groff","year":"2025","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01098_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1470-2045(25)00267-0","article-title":"Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study","volume":"26","author":"Gui","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3171\/2023.2.JNS222751","article-title":"Is brain invasion sufficient as a stand-alone criterion for grading atypical meningioma?","volume":"139","author":"Li","year":"2023","journal-title":"J Neurosurg"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01098_bib23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/neuonc\/noac032","article-title":"The impact of brain invasion criteria on the incidence and distribution of WHO grade 1, 2, and 3 meningiomas","volume":"24","author":"Rebchuk","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","article-title":"Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas","volume":"146","author":"Wang","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/neuonc\/now029","article-title":"PIK3CA mutations in meningioma","volume":"18","author":"Zadeh","year":"2016","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01098_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01098_bib30","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01098_bib31","first-page":"1","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"21","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41588-025-02475-w","article-title":"A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification","volume":"58","author":"Maas","year":"2026","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noag022","article-title":"Meningioma microenvironment harbors a rich immune landscape that evolves with biological state","volume":"28","author":"Guo","year":"2026","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01098_bib34","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/s41591-024-02995-8","article-title":"Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning","volume":"30","author":"Hoang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01098_bib35","article-title":"Morphological set enrichment enables interpretable prognostication and molecular profiling of meningiomas","author":"Ayad","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.neurot.2026.e01098_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1536751","article-title":"Performance of deep learning models for automatic histopathological grading of meningiomas: a systematic review and meta-analysis","volume":"16","author":"Noori Mirtaheri","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e01098_bib37","series-title":"Establishing the utility of deep-learning for H&E-based meningioma molecular classification and outcome prediction","author":"Landry","year":"2026"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: Report from the response assessment in neuro-oncology working group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib39","first-page":"234","article-title":"Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-025-00811-1","article-title":"A multi-modal deep learning model for prediction of Ki-67 for meningiomas using pretreatment MR images","volume":"9","author":"Chen","year":"2025","journal-title":"npj Precis Onc"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.15430\/JCP.2022.27.3.192","article-title":"A deep learning architecture for meningioma brain tumor detection and segmentation","volume":"27","author":"Anita","year":"2022","journal-title":"J Cancer Prev"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nec.2015.11.007","article-title":"Predicting meningioma consistency on preoperative neuroimaging studies","volume":"27","author":"Shiroishi","year":"2016","journal-title":"Neurosurg Clin"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib43","article-title":"An MRI-based deep transfer learning radiomics nomogram for predicting meningioma grade","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e01098_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657288","article-title":"Preoperative prediction of meningioma consistency via machine learning-based radiomics","volume":"11","author":"Zhai","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.neurot.2026.e01098_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2026.103978","article-title":"A single MRI scan contains sufficient imaging information for accurate prediction of meningioma growth risk","volume":"49","author":"Sadeghzadeh","year":"2026","journal-title":"Neuroimage, Clin"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib46","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.acra.2023.10.059","article-title":"Development of a clinicopathological-radiomics model for predicting progression and recurrence in meningioma patients","volume":"31","author":"He","year":"2024","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13014-025-02613-y","article-title":"Exploring a recurrence model for atypical meningioma based on multiparametric MRI radiomic and clinical characteristics: a multicenter retrospective cohort study","volume":"20","author":"Song","year":"2025","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib48","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01098_bib49","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas","volume":"42","author":"Henze","year":"2001","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01098_bib51","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01098_bib52","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","article-title":"Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI","volume":"58","author":"Kunz","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib53","article-title":"[68Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas","volume":"3","author":"Mahase","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ijrobp.2022.04.009","article-title":"68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma","volume":"113","author":"Perlow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01098_bib55","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma-report of the RANO\/PET group","volume":"19","author":"Galldiks","year":"2017","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib56","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s10143-020-01428-7","article-title":"The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy","volume":"44","author":"Behling","year":"2021","journal-title":"Neurosurg Rev"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01098_bib57","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/cancers14082007","article-title":"The simpson grading: is it still valid?","volume":"14","author":"Chotai","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00701-013-1923-6","article-title":"Simpson grade: an opportunity to reassess the need for complete resection of meningiomas","volume":"156","author":"Heald","year":"2014","journal-title":"Acta Neurochir"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3171\/2010.3.JNS091971","article-title":"The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization grade I meningiomas","volume":"113","author":"Sughrue","year":"2010","journal-title":"J Neurosurg"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib60","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","article-title":"The Simpson grading revisited: aggressive surgery and its place in modern meningioma management","volume":"125","author":"Gousias","year":"2016","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1227\/neu.0000000000003324","article-title":"The impact of MRI-defined extent of resection across meningioma DNA methylation groups: Re-evaluating surgery in the era of meningioma molecular classification","volume":"97","author":"Morshed","year":"2025","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib63","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3171\/jns.1991.74.4.0552","article-title":"Stereotactic radiosurgery of meningiomas","volume":"74","author":"Kondziolka","year":"1991","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01098_bib64","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/neuros\/nyy009","article-title":"Stereotactic radiosurgery for benign (World Health Organization grade I) cavernous sinus meningiomas-International stereotactic radiosurgery Society (ISRS) practice guideline: a systematic review","volume":"83","author":"Lee","year":"2018","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/noab132","article-title":"An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study","volume":"24","author":"Sheehan","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/neuonc\/noac137","article-title":"Low-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539","volume":"25","author":"Rogers","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","article-title":"Intermediate-risk meningioma: initial outcomes from NRG oncology RTOG 0539","volume":"129","author":"Rogers","year":"2018","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib68","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","article-title":"High-risk Meningioma: Initial Outcomes from NRG Oncology\/RTOG 0539","volume":"106","author":"Rogers","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.neurot.2026.e01098_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s13063-015-1040-3","article-title":"The ROAM\/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial","volume":"16","author":"Jenkinson","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.neurot.2026.e01098_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01804-0","article-title":"Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM\/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial","author":"Jenkinson","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib71","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2024.07.003","article-title":"A prospective, phase II study of 177Lu-Dotatate in patients with Surgery- and radiation-refractory meningioma: results of the WHO grade II\/III cohort","volume":"120","author":"Merrell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01098_bib72","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib73","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00259-025-07555-x","article-title":"[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data","volume":"53","author":"Boursier","year":"2026","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2967\/jnumed.125.269633","article-title":"[177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial","volume":"67","author":"Albert","year":"2026","journal-title":"J Nucl Med"},{"issue":"suppl ment_5","key":"10.1016\/j.neurot.2026.e01098_bib75","article-title":"TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)","volume":"27","author":"Kurz","year":"2025","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib76","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tips.2026.01.001","article-title":"Targeted alpha therapy (r)evolution: emerging nuclides for clinical applications","volume":"47","author":"Pedersen","year":"2026","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neurot.2026.e01098_bib77","doi-asserted-by":"crossref","unstructured":"Ovid [Internet]. [cited 2026 Sep. 18]. Preliminary evaluation of 225 Ac\/177 Lu-DOTATATE... : Clin Nucl Med. Available from:: https:\/\/www.ovid.com\/jnls\/nuclearmed\/fulltext\/10.1097\/rlu.0000000000006536∼preliminary-evaluation-of-225-ac177-lu-dotatate-prrt-in doi:10.1097\/RLU.0000000000006536.","DOI":"10.1097\/RLU.0000000000006536"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01098_bib78","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noaf009","article-title":"Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design","volume":"27","author":"Kotecha","year":"2025","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01098_bib79","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01098_bib81","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","article-title":"Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies","volume":"86","author":"Karsy","year":"2016","journal-title":"World Neurosurg"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib82","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/neuonc\/noab243","article-title":"Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)","volume":"24","author":"Preusser","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib83","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib84","article-title":"A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma","volume":"4","author":"Kumthekar","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib86","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01098_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01098_bib88","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01098_bib89","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-025-04141-4","article-title":"Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 alliance A071401 trial","volume":"32","author":"Brastianos","year":"2026","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01098_bib90","first-page":"1","article-title":"DNA methylation-based classification for central nervous system tumours: a health technology assessment","volume":"25","year":"2025","journal-title":"Ont Health Technol Assess Ser"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:52Z","timestamp":1792720372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002680"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01098","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningioma in the modern era: Updates in stratification and therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01098"}}